论文部分内容阅读
目的 :评价造血干细胞移植 (HSCT)治疗血液病的临床疗效及并发症。方法 :112例血液病患者行HSCT ,其中自体HSCT(auto -HSCT) 52例 ,混合HSCT(mixed -HSCT) 3 3例 ,异基因HSCT(allo -HSCT) 2 7例。结果 :随访平均 64个月 (2月～ 2 0年 ) ,62例 (55.4% )无病存活 ,其中 :auto -HSCT2 7/ 52例 (51.9% ) ,mixed -HSCT19/ 3 3例 (57.6% ) ,allo -HSCT16/ 2 7例 (59.3 % )。 51例(45.5% )死亡 ,其中 :auto -HSCT :18/ 52例 (3 4 .6% )复发死亡 ;7/ 52例 (13 .5% )移植相关死亡 ;mixed -HSCT :19/ 3 3例 (2 4.2 % )复发死亡 ;6/ 3 3例 (18.2 % )移植相关死亡 ;allo -HSCT :3 / 2 7例 (11.1% )复发死亡 ;2 / 2 7例 (7.4% )GVHD引起肝功衰竭死亡 ;6/2 7例 (2 2 .1% )移植相关死亡。结论 :HSCT治疗疗效确切 ,可提高长期无病生存
Objective: To evaluate the clinical efficacy and complications of hematopoietic stem cell transplantation (HSCT) in the treatment of hematological diseases. Methods: One hundred and twelve patients with hematologic diseases underwent HSCT, including 52 cases of auto-HSCT, 23 cases of mixed-HSCT and 27 cases of allo-HSCT. Results: Sixty-two patients (55.4%) survived without disease over an average follow-up of 64 months (range, 2 months to 20 years), including 7 of 52 (51.9%) cases of auto-HSCT2 and 57.6% ), allo-HSCT16 / 2 7 cases (59.3%). Fifty-one patients (45.5%) died of auto-HSCT: 18/52 (34.6%) died of recurrence; 7/52 (13.5%) died of graft-versus-host disease; Allograft-related deaths were found in 6/3 (18.2%) cases; allo-HSCT: 3/2 7 (11.1%) were relapsed and died; 2/27 (7.4% Twenty-seven patients (21.2%) died of transplant-related death. Conclusion: HSCT is effective and can improve long-term disease-free survival